Abstract
HPV (human papilloma virus, Papillomavirus of the family Papovaviridae) infection is probably the most frequent sexually transmitted disease. At least 13 HPV genotypes are classified as carcinogenic in the relation to the cervical cancer.
The prevention of cervical cancer using either the bivalent (Cervarix(R)) or the quadrivalent (Silgard(R), Gardasil(R)) HPV vaccine is the goal of immunization programs in many countries. First data of efficiency against cancers at other localisations also emerge.
Large trials for both vaccines find efficacy against HPV-related infection and different HPV associated diseases. The indications written in SPC (Summaries of Product's Characteristics) of both vaccines become broader.
Randomized control trials demonstrate robust antibody responses and hig efficacy also in men. Several countries recommend gender-neutral vaccination.
The immunobridging studies show that two doses of both HPV vaccines induce non-inferior antibody titers in young adolescents to antibody titers elicited in women 15-25 years old with three doses of the vaccine. Since 2012, vaccination of girls at the age of 13-14 years has been covered from the health insurance in the Czech Republic.